Literature DB >> 33801203

CD8+ T Cell Responses during HCV Infection and HCC.

Maike Hofmann1, Catrin Tauber1, Nina Hensel1,2, Robert Thimme1.   

Abstract

Chronic hepatitis C virus (cHCV) infection is a major global health burden and the leading cause of hepatocellular carcinoma (HCC) in the Western world. The course and outcome of HCV infection is centrally influenced by CD8+ T cell responses. Indeed, strong virus-specific CD8+ T cell responses are associated with spontaneous viral clearance while failure of these responses, e.g., caused by viral escape and T cell exhaustion, is associated with the development of chronic infection. Recently, heterogeneity within the exhausted HCV-specific CD8+ T cells has been observed with implications for immunotherapeutic approaches also for other diseases. In HCC, the presence of tumor-infiltrating and peripheral CD8+ T cell responses correlates with a favorable prognosis. Thus, tumor-associated and tumor-specific CD8+ T cells are considered suitable targets for immunotherapeutic strategies. Here, we review the current knowledge of CD8+ T cell responses in chronic HCV infection and HCC and their respective failure with the potential consequences for T cell-associated immunotherapeutic approaches.

Entities:  

Keywords:  CD8+ T cells; HCC; HCV; T cell exhaustion; checkpoint blockade therapy

Year:  2021        PMID: 33801203      PMCID: PMC7957882          DOI: 10.3390/jcm10050991

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  105 in total

1.  Memory-like HCV-specific CD8+ T cells retain a molecular scar after cure of chronic HCV infection.

Authors:  Nina Hensel; Zuguang Gu; Dominik Wieland; Katharina Jechow; Janine Kemming; Sian Llewellyn-Lacey; Emma Gostick; Oezlem Sogukpinar; Florian Emmerich; David A Price; Bertram Bengsch; Tobias Boettler; Christoph Neumann-Haefelin; Roland Eils; Christian Conrad; Ralf Bartenschlager; Dominic Grün; Naveed Ishaque; Robert Thimme; Maike Hofmann
Journal:  Nat Immunol       Date:  2021-01-04       Impact factor: 25.606

2.  Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing.

Authors:  Chunhong Zheng; Liangtao Zheng; Jae-Kwang Yoo; Huahu Guo; Yuanyuan Zhang; Xinyi Guo; Boxi Kang; Ruozhen Hu; Julie Y Huang; Qiming Zhang; Zhouzerui Liu; Minghui Dong; Xueda Hu; Wenjun Ouyang; Jirun Peng; Zemin Zhang
Journal:  Cell       Date:  2017-06-15       Impact factor: 41.582

Review 3.  Hepatitis C.

Authors:  C Wendy Spearman; Geoffrey M Dusheiko; Margaret Hellard; Mark Sonderup
Journal:  Lancet       Date:  2019-10-19       Impact factor: 79.321

4.  Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

Authors:  Sharon E Frey; Michael Houghton; Stephen Coates; Sergio Abrignani; David Chien; Domenico Rosa; Piero Pileri; Ranjit Ray; Adrian M Di Bisceglie; Paola Rinella; Heather Hill; Mark C Wolff; Viola Schultze; Jang H Han; Bruce Scharschmidt; Robert B Belshe
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

5.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

6.  Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory.

Authors:  Travis A Doering; Alison Crawford; Jill M Angelosanto; Michael A Paley; Carly G Ziegler; E John Wherry
Journal:  Immunity       Date:  2012-11-15       Impact factor: 31.745

7.  The immune contexture of hepatocellular carcinoma predicts clinical outcome.

Authors:  Friedrich Foerster; Moritz Hess; Aslihan Gerhold-Ay; Jens Uwe Marquardt; Diana Becker; Peter Robert Galle; Detlef Schuppan; Harald Binder; Ernesto Bockamp
Journal:  Sci Rep       Date:  2018-03-29       Impact factor: 4.379

8.  TOX is a critical regulator of tumour-specific T cell differentiation.

Authors:  Andrew C Scott; Friederike Dündar; Paul Zumbo; Smita S Chandran; Christopher A Klebanoff; Mojdeh Shakiba; Prerak Trivedi; Laura Menocal; Heather Appleby; Steven Camara; Dmitriy Zamarin; Tyler Walther; Alexandra Snyder; Matthew R Femia; Elizabeth A Comen; Hannah Y Wen; Matthew D Hellmann; Niroshana Anandasabapathy; Yong Liu; Nasser K Altorki; Peter Lauer; Olivier Levy; Michael S Glickman; Jonathan Kaye; Doron Betel; Mary Philip; Andrea Schietinger
Journal:  Nature       Date:  2019-06-17       Impact factor: 49.962

9.  Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.

Authors:  Naglaa H Shoukry; Arash Grakoui; Michael Houghton; David Y Chien; John Ghrayeb; Keith A Reimann; Christopher M Walker
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

Review 10.  Update in global trends and aetiology of hepatocellular carcinoma.

Authors:  Prashanth Rawla; Tagore Sunkara; Pradhyumna Muralidharan; Jeffrey Pradeep Raj
Journal:  Contemp Oncol (Pozn)       Date:  2018-09-30
View more
  5 in total

1.  Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges.

Authors:  Joachim Lupberger; Thomas F Baumert
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.241

2.  The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility.

Authors:  Jinlong Liang; Jingyi Wang; Jinshui Zeng; Zhibo Bai; Zhiyuan Zheng; Yue Zheng; Fengqi Jiang; Di Wu
Journal:  Dis Markers       Date:  2022-08-22       Impact factor: 3.464

3.  The role of tumor-infiltrating B cells in the tumor microenvironment of hepatocellular carcinoma and its prognostic value: a bioinformatics analysis.

Authors:  Jixue Zou; Chubin Luo; Haoyang Xin; Tongchun Xue; Xiaoying Xie; Rongxin Chen; Lan Zhang
Journal:  J Gastrointest Oncol       Date:  2022-08

Review 4.  Prospects and Challenges for T Cell-Based Therapies of HCC.

Authors:  Norman Woller; Sophie Anna Engelskircher; Thomas Wirth; Heiner Wedemeyer
Journal:  Cells       Date:  2021-06-30       Impact factor: 6.600

5.  The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.

Authors:  Jie Zhu; Peiqi Fang; Chong Wang; Meixiu Gu; Baishen Pan; Wei Guo; Xinrong Yang; Beili Wang
Journal:  Cancer Med       Date:  2021-10-04       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.